A sting in the tale - - Chromatography Online
A sting in the tale

The Column
Volume 8, Issue 21

Two novel peptides have been identified within the crude extract of Asian scorpion Buthus martensi Karsch venom using two-dimensional high perfomance liquid chromatography (2D-HPLC) and tandem mass spectrometry (MS–MS). Historically used in Chinese medicine to treat heart disease, the venom has potential applications in the development and identification of new drugs. Earlier this year, a study was published showing that peptides isolated from scorpion venom had anti-bacterial properties, specifically effective against established antibiotic‑resistant bacteria.1

Scorpion venom is a complex mixture of proteins, including a range of neurotoxic peptides that selectively block cell-to-cell signalling by selectively binding to ion-channels. These peptides can be used in pharmocological studies to block specific channels and signalling, potentially revealing new drug targets.

Based on genetic data, within the Buthus martensi Karsch venom it is estimated that there are 86 toxins, but only the presence of 46 peptides have been confirmed.2 The previous methods have been regarded as too low a sensitivity to detect all the petides present.

A group of investigators in China2 has identified two novel peptides, previously predicted to be present in scorpion venom-based on genetic data, but otherwise not found. Offline orthogonal two‑dimensional reversed-phase liquid chromatography/hydrophilic interaction liquid chromatography (2D-RPLC/HILIC) purification and collision-induced dissociation tandem mass spectrometry (CID-MS–MS) technique was used. Using bioinformatics the two novel peptides were predicted to be selective inhibitors of the potassium channel toxin α-KTx17 subfamily.

This research therefore has the potential to advance drug development through the discovery of new drug targets.

1. L. Cao et al., PLoS ONE, DOI:10.1371/journal.pone.0040135 (2012).

2. J. Xu et al., Proteomics, 12, 3076–3084 (2012).

This story originally appeared in The Column. Click here to view that issue.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters
Global E-newsletters subscribe here:




 

LCGC COLUMNISTS 2014

Column Watch: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments. LATEST: When Bad Things Happen to Good Food: Applications of HPLC to Detect Food Adulteration


Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: HPLC for Characterization and Quality Control of Therapeutic Monoclonal Antibodies


MS — The Practical Art: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis


LC Troubleshooting: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: How Much Can I Inject? Part I: Injecting in Mobile Phase


More LCGC Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>


Source: The Column,
Click here